CAPTRUST Financial Advisors
CLSD

CAPTRUST Financial Advisors’s Clearside Biomedical CLSD Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,800
Closed -$69.6K – 2645
2025
Q2 		$69.6K Hold
5,800
– – ﹤0.01% 2400
2025
Q1 		$79.9K Sell
5,800
-947
-14% -$13.6K ﹤0.01% 2256
2024
Q4 		$96.1K Buy
6,747
+565
+9% +$9.29K ﹤0.01% 2207
2024
Q3 		$118K Buy
6,182
+382
+7% +$6.52K ﹤0.01% 2194
2024
Q2 		$113K Buy
5,800
+2,467
+74% +$47.7K ﹤0.01% 2105
2024
Q1 		$76.5K Hold
3,333
– – ﹤0.01% 2068
2023
Q4 		$58.5K Hold
3,333
– – ﹤0.01% 2578
2023
Q3 		$43.5K Buy
3,333
+1,727
+108% +$26.2K ﹤0.01% 2493
2023
Q2 		$27K Buy
1,606
+206
+15% +$3.55K ﹤0.01% 2455
2023
Q1 		$21.8K Buy
+1,400
New +$27.2K ﹤0.01% 2250
2022
Q3 		– Sell
-293
Closed -$6K – 2424
2022
Q2 		$6K Buy
293
+286
+4,086% +$6.94K ﹤0.01% 3986
2022
Q1 		$0 Hold
7
– – ﹤0.01% 4938
2021
Q4 		$0 Buy
+7
New +$453 ﹤0.01% 4776

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $6.15B AUM 22.62% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAPTRUST Financial Advisors's CLSD Position: Q3 2025 in Review

CAPTRUST Financial Advisors sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 5,800 shares — an estimated $69.6K sold.

CAPTRUST Financial Advisors first reported a position in CLSD in Q4 2021 and held it in 13 quarters. The position peaked at $118K in Q3 2024. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.

  • CAPTRUST Financial Advisors reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 5,800 Clearside Biomedical shares in Q3 2025, an estimated $69.6K.
  • CAPTRUST Financial Advisors first reported a position in Clearside Biomedical in Q4 2021 and held it in 13 quarters.
  • CAPTRUST Financial Advisors's Clearside Biomedical position peaked at $118K in Q3 2024.
  • 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2025, filed 19 Nov 2025.